France assesses on two scales — one sets reimbursement eligibility, the other anchors the price — and an early-access route can set the effective price before either concludes.
Two ratings decide a medicine's position in France. SMR determines whether it is reimbursed and at what statutory rate. ASMR measures added value against existing therapy and anchors the price negotiated with the pricing committee. An asset can be reimbursed and still be priced modestly, because the two questions are answered separately.
The scope of the reimbursement opinion matters as much as the rating. Where a favourable opinion is given for one line of therapy only, every patient outside it leaves the addressable population before price is discussed at all — a restriction that shapes commercial value more than the price itself.
France also runs an early-access route that admits a medicine before its European licence takes effect, with rebates accruing from the first invoice and reconciled once the definitive price lands. An asset can therefore be treating patients, and accruing a liability, months before its formal assessment concludes. A launch plan that starts at the definitive appraisal has already missed the decision that set the price.
AXLRx France reports work through that sequence: the early-access opportunity and its cost, the reimbursement scope to expect, and the negotiation the rating sets up.
Iptacopan reached French PNH patients through early access, before EU marketing authorisation took effect. HAS granted accès précoce two weeks ahead of it. Any new PNH entrant must be dossier-ready for this track before, not after, EU approval.
France's PMSI hospital database counts 897 PNH patients over five years; Orphanet's older estimate puts national prevalence at 850-1,000. Only 270 of them, per the manufacturer's own estimate, are eligible for a second-line oral agent.
HAS reimburses iptacopan second-line only, after at least six months on a C5 inhibitor, while ravulizumab holds first-line. France split the anti-complement class by line of therapy, not by price.
France's PMSI hospitalisation database identified 897 PNH patients between 2018 and 2022, putting prevalence near 1 in 94,000. That is below the 1-in-70,000-to-80,000 range Orphanet and France's national rare disease plan have long cited.
France's national hospitalisation database puts PNH prevalence near 1 in 94,000, or 897 patients from 2018 to 2022. That is lower than the 16-per-million figure Germany's DGHO Onkopedia guideline borrows from French and UK registries.
France prices PNH on two tracks. Ravulizumab holds first-line; iptacopan is reimbursed second-line only, and reached patients through early access two weeks before its EU marketing authorisation took effect.
Saint-Louis Hospital anchors France's MaRIH-coordinated PNH reference network of 14 competence centres. Only 24 of the 50-plus centres in the national clone-observatory network actively report into it. That kind of institutional structure is exactly what this workbook sizes before any individual name enters it.
France reimburses iptacopan second-line only, after at least six months on a C5 inhibitor, while ravulizumab holds the first-line position. The restriction, not the price, is what defines the addressable population.